Methylated free-circulatingHPP1DNA is an early response marker in patients with metastatic colorectal cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Methylated free-circulatingHPP1DNA is an early response marker in patients with metastatic colorectal cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 140, Issue 9, Pages 2134-2144
Publisher
Wiley
Online
2017-01-26
DOI
10.1002/ijc.30625
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
- (2015) J. Tie et al. ANNALS OF ONCOLOGY
- Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
- (2015) T F Hansen et al. BRITISH JOURNAL OF CANCER
- Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
- (2015) J. Randolph Hecht et al. CANCER TREATMENT REVIEWS
- Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
- (2015) Volker Heinemann et al. EUROPEAN JOURNAL OF CANCER
- Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
- (2015) Susanna Hegewisch-Becker et al. LANCET ONCOLOGY
- Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer
- (2014) Alexander B Philipp et al. BMC CANCER
- A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer
- (2014) Jorge Barbazán et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
- (2013) J M Jürgensmeier et al. BRITISH JOURNAL OF CANCER
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generation and characterization of Tmeff2 mutant mice
- (2012) Tian Rui Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab
- (2012) Roberto Petrioli et al. CANCER INVESTIGATION
- Prognostic role of methylated free circulating DNA in colorectal cancer
- (2012) Alexander B. Philipp et al. INTERNATIONAL JOURNAL OF CANCER
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009
- (2010) R. Adam et al. ANNALS OF ONCOLOGY
- Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
- (2009) S. Welch et al. ANNALS OF ONCOLOGY
- Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence
- (2009) Andreas Herbst et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now